Impact of Anthracyclines in Genomic High Risk, Node-Negative, HR-Positive/HER2-Negative Breast Cancer. Chen N, Freeman JQ, Yarlagadda S, Atmakuri A, et al. Ann Oncol 2025 Sep 17:S0923-7534(25)00922-6. doi: 10.1016/j.annonc.2025.

Read + Share

Amedeo Smart

Independent Medical Education

Chen N, Freeman JQ, Yarlagadda S, Atmakuri A, et al. Impact of Anthracyclines in Genomic High Risk, Node-Negative, HR-Positive/HER2-Negative Breast Cancer. Ann Oncol 2025 Sep 17:S0923-7534(25)00922-6. doi: 10.1016/j.annonc.2025.
PMID: 40972946